New Two-Pronged attack on tough lymphoma shows early promise
NCT ID NCT05149391
Summary
This early-stage study tested a new type of personalized cell therapy called C-CAR039 in three patients with B-cell lymphoma that had returned or stopped responding to standard treatments. The therapy involves modifying a patient's own immune cells to recognize and attack two common targets on lymphoma cells (CD19 and CD20). The main goal was to check the safety of the treatment and see how the modified cells behaved in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.